Sector News

Canada’s Concordia Healthcare to Buy Amdipharm

September 9, 2015
Life sciences

Concordia Healthcare Corp. on Tuesday said it would buy U.K.-based Amdipharm Mercury Ltd. from European private-equity firm Cinven for about $1.2 billion in cash and around $700 million in stock, a deal the Canadian pharmaceutical company calls transformational.

Concordia said the acquisition, valued at about $3.5 billion including debt, gives it a platform to expand globally and adds more than 190 niche pharmaceutical products to its current portfolio.

“This acquisition is a key milestone and pivotal turning point in Concordia’s strategy, which gives us the platform to take our business to the next level,” Concordia Chief Executive Mark Thompson said in a statement. “The combination of our highly complementary yet geographically diverse businesses is truly transformational.”

The deal further bolsters Oakville, Ontario-based Concordia’s operations after its $1.2 billion purchase earlier this year of certain assets of Covis Pharma Holdings S.a.r.l. Covis helped the Canadian firm nearly triple its revenue in the first half of this year to $114 million. In late June, Concordia listed on Nasdaq to help increase its exposure.

Amdipharm, or AMCo, was created by Cinven in 2012 through the merger of two niche pharmaceutical companies, Amdipharm and Mercury Pharma Group. It acquired both companies in 2012, paying £465 million ($716 million) for Mercury and £367 million for Amdipharm. The group has grown further through a series of smaller deals.

AMCo sells off-patent drugs in therapy areas for which treatment regimens are well-established and less likely to face competition from innovative new drugs. It had revenue in 2014 of £293 million in 2014, up 21.5% from a year earlier.

Concordia said the combined company, on a pro forma basis, is expected to have revenue of between $870 million and $920 million for 2015. It also expects the deal to boost its adjusted share earnings by more than 35% in the first full year.

The Canadian company will issue 8.49 million shares under the deal, which will give Cinven a 19.9% stake in Concordia. Closing is expected in the fourth quarter.

By Judy McKinnon

Source: Wall Street Journal

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach